These results are highly significant as they add vital knowledge for clinical decisions regarding precision medicine strategies for using BET inhibitors as a single agent or in combination to treat patients with aggressive treatment refractory B-cell lymphomas.
← all excerpts
Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies.
1
—
—